Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics Limited (AU:PER)
OTHER OTC:PER
PER Stock Chart & Stats
AU$0.01
<AU$0.01(12.50%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(12.50%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume20.44M
Average Volume (3M)2.49M
Market Cap
AU$9.24M
Enterprise Value-AU$3.02M
Total Cash (Recent Filing)AU$10.17M
Total Debt (Recent Filing)AU$25.86K
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,087,437,600
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$3.58M
Percheron Therapeutics News
PER FAQ
What was Percheron Therapeutics Limited’s price range in the past 12 months?
Percheron Therapeutics Limited lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Percheron Therapeutics Limited’s market cap?
Percheron Therapeutics Limited’s market cap is AU$9.24M.
When is Percheron Therapeutics Limited’s upcoming earnings report date?
Percheron Therapeutics Limited’s upcoming earnings report date is Feb 25, 2026 which is in 61 days.
How were Percheron Therapeutics Limited’s earnings last quarter?
Percheron Therapeutics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Percheron Therapeutics Limited overvalued?
According to Wall Street analysts Percheron Therapeutics Limited’s price is currently Overvalued.
Does Percheron Therapeutics Limited pay dividends?
Percheron Therapeutics Limited does not currently pay dividends.
What is Percheron Therapeutics Limited’s EPS estimate?
Percheron Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics Limited have?
Percheron Therapeutics Limited has 1,087,437,600 shares outstanding.
What happened to Percheron Therapeutics Limited’s price movement after its last earnings report?
Percheron Therapeutics Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Percheron Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Percheron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PER Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$8.5K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-151.35%
Trailing 12-Months
Asset Growth
-16.01%
Trailing 12-Months
Company Description
Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Options Prices
Currently, No data available
---